New drug combo aims to boost stem cell transplant success in hard-to-treat lymphoma

NCT ID NCT07365306

First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 9 times

Summary

This study tests whether adding the drug epcoritamab to standard chemotherapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatment. About 43 adults will receive the combination before an autologous stem cell transplant. The goal is to see if this approach leads to complete remission before the transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Atlanta Cancer Center

    NOT_YET_RECRUITING

    Newnan, Georgia, 30265, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • City of Hope at Chicago

    NOT_YET_RECRUITING

    Zion, Illinois, 60099, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.